Comparison of rapid and long-lasting antidepressant effects of negative modulators of α5-containing GABAA receptors and (R)‑ketamine in a chronic social defeat stress model
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The negative allosteric modulators (NAMs: L‐655,708 and MRK‐016) of &agr;5 subunit‐containing GABAA receptors are reported to show rapid‐acting antidepressant effects in rodents. However, there are no reports comparing these NAMs and (R)‐ketamine, (R)‐enantiomer of the rapid‐acting antidepressant ketamine, in a chronic social defeat stress (CSDS) model. Here we measured expression of &agr;5 GABAA receptor in the brain regions from CSDS susceptible mice and postmortem brain samples from depressed patients. Expression of &agr;5 GABAA receptor in the prefrontal cortex and hippocampus from CSDS susceptible mice was significantly higher than that of control mice. Furthermore, expression of &agr;5 GABAA receptor in the parietal cortex from depressed patients was also higher than that of control subjects. In the tail suspension and forced swimming tests, (R)‐ketamine and MRK‐016 significantly attenuated the increased immobility time in the susceptible mice, compared with the vehicle‐treated group. In the sucrose preference test, (R)‐ketamine and MRK‐016 significantly enhanced the reduced preference in CSDS susceptible mice two days after a single injection. Unlike (R)‐ketamine, MRK‐016 did not attenuate the reduced sucrose preference in susceptible mice 7days after a single injection. In contrast, L‐655,708 did not show antidepressant effects in the same model. In conclusion, this study shows that increased levels of &agr;5 GABAA receptors in the PFC and hippocampus may play a role in depression‐like phenotype after CSDS. It is unlikely that MRK‐016 has long‐lasting antidepressant effects although it elicits rapid‐acting antidepressant effects. HIGHLIGHTS(R)‐ketamine showed rapid and long‐lasting antidepressant effects.MRK‐016 showed rapid antidepressant effects.MRK‐016 did not show long‐lasting antidepressant effects.L‐655,708 did not show antidepressant effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu121 · Cited by 103
Self-citationRetractedThe mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
A standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 2×
“A single sub-anesthetic dose of (R,S)‑ketamine produces a rapid and robust antidepressant response in two-thirds of patients with treatment-resistant depression, which can last for over a week (Aan Het Rot et al., 2012; Berman et al., 2000; Diazgranados et al., 2010; Zarate et al., 2006, 2012).”
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · cited 2×
“Importantly, it is also known that MRK-016 is a full inverse agonist at α5 subtype whereas L-655,708 is a very weak inverse agonist at α5 subtype (Rudolph and Knoflach, 2011).”
BackgroundR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationZhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
Self-citationTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482 · cited 1×
“Therefore, the development of novel drugs capable of inducing rapid and robust antidepressant responses in treatment-resistant depressed patients is unmet need (Chaki, 2017; Duman, 2018; Garay et al., 2018; Hashimoto, 2015; Krystal et al., 2013; Monteggia and Zarate, 2015; Murrough et al., 2017; Witkin et al., 2018).”
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 6×
“It is reported that L-655,708 (0.7 mg/kg) and MRK-016 (3.0 mg/kg) rapidly reversed loss of sucrose preference and social interaction behaviors in rats after CRS or CUS (Fischell et al., 2015), and that MRK016 (3.0 mg/kg) reversed reduced sucrose preference in mice after CRS (Zanos et al., 2017).”
InfluentialRudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Zhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289
Self-citationAntidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183
Self-citationAntidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Shirayama, Y., Yang, C., Zhang, J.-C., Ren, Q., Yao, W., & Hashimoto, K. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.09.002 · Cited by 137 · cited 9×
“Collectively, it is probable that CSDS causes increased α5 GABAA receptors in the hippocampus and PFC, but decreased α5 GABAA receptors in the NAc, resulting in depression-like behavior in mice.”
InfluentialSelf-citationHashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Self-citationFischell, J., Van Dyke, A. M., Kvarta, M. D., LeGates, T. A., & Thompson, S. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.112 · Cited by 122 · cited 11×
“It is reported that L-655,708 (0.7 mg/kg) and MRK-016 (3.0 mg/kg) rapidly reversed loss of sucrose preference and social interaction behaviors in rats after CRS or CUS (Fischell et al., 2015), and that MRK016 (3.0 mg/kg) reversed reduced sucrose preference in mice after CRS (Zanos et al., 2017).”
BackgroundResultInfluentialZanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0285-16.2017 · Cited by 106
Yang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.034 · Cited by 91 · cited 1×
“abuse potential in rodents and monkeys (Hashimoto et al., 2017; Tian et al., 2018; Yang et al., 2015b; Yang et al., 2016).”
Self-citationCarreno, F. R., Collins, G. T., Frazer, A., & Lodge, D. J. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx003 · Cited by 31 · cited 1×
“Furthermore, L-655,708 (3mg/ kg) is reported to show sustained (1 week) antidepressant-like effects in the forced swimming test in control rats without depression-like phenotype (Carreno et al., 2017).”
Cited by
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Conversely, L655,708 did not produce any antidepressant effect in the same model.(171)”
BackgroundSelf-citationChang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Self-citationHu, Y.-T., Tan, Z.-L., Hirjak, D., & Northoff, G. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02193-x · Cited by 127
Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Metadata
- Authors
- Xiong, Z., Zhang, K., Ishima, T., Ren, Q., Chang, L., Chen, J., & Hashimoto, K.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 175
- Pages
- 139-145
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2898449822
- Cited by
- 29
- References
- 23
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.